ADC Therapeutics (ADCT) Research & Development (2020 - 2026)
ADC Therapeutics' (ADCT) quarterly Research & Development came in at $17.4 million in Q2 2026, down 42.29% year-over-year from $30.1 million in Q2 2025, and down 12.63% quarter-over-quarter from $19.9 million in Q1 2026.
Powered by 
Analysis
ADC Therapeutics (ADCT) Research & Development (2020 - 2026) Analysis & Trends
ADC Therapeutics has disclosed Research & Development across 7 years of filings, most recently posting $17.4 million for Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 1.87 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 1.76 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 993.80 Mn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 1.63 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | -486.00 Mn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 651.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 413.13 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 529.60 Mn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 210.03 Mn |
| 10 | ADC Therapeutics | 172.04 Mn | -47.07 Mn | 17.14 Mn | 17.37 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 17.37 Mn |
| Mar 31, 2026 | 19.88 Mn |
| Sep 30, 2025 | 26.80 Mn |
| Jun 30, 2025 | 30.09 Mn |
| Mar 31, 2025 | 28.93 Mn |
| Sep 30, 2024 | 32.50 Mn |
| Jun 30, 2024 | 24.30 Mn |
| Mar 31, 2024 | 25.74 Mn |
| Sep 30, 2023 | 27.08 Mn |
| Jun 30, 2023 | 31.34 Mn |
| Mar 31, 2023 | 39.48 Mn |
| Sep 30, 2022 | 41.68 Mn |
| Jun 30, 2022 | 48.54 Mn |
| Mar 31, 2022 | 48.95 Mn |
| Sep 30, 2021 | 36.81 Mn |
| Jun 30, 2021 | 39.53 Mn |
| Mar 31, 2021 | 39.17 Mn |
| Sep 30, 2020 | 32.16 Mn |
| Jun 30, 2020 | 25.95 Mn |
| Mar 31, 2020 | 35.38 Mn |